NetworkNewsBreaks

FridayNov 04, 2016 11:18 am

Singlepoint, Inc.’s (SING) SingleSeed to Address Payment Challenges of Cannabis Industry

The marijuana industry is on pace to reach $20.6 billion by 2020, a figure that could tick higher as more states vote on legalization for medical or recreational use. One area lacking in this burgeoning industry is payment solutions. Singlepoint’s (OTC: SING) SingleSeed subsidiary is rising to the challenge, “awakening from a quiet period to provide state-of-the-art payment solutions and mobile marketing aimed at helping industry players grow their businesses safely and securely … SingleSeed and its processing partner have extensive relationships and technology partners they can leverage to develop the necessary apps and tools that will help protect the…

Continue Reading

FridayNov 04, 2016 11:16 am

FuelCell Energy, Inc. (FCEL) Installs 5.6MW Power Plant for Pfizer; Shares Climb

Shares of FuelCell Energy (NASDAQ: FCEL) are higher after the company said it has completed the construction and commercial operations of a previously announced 5.6 megawatt fuel cell project on Pfizer, Inc.’s (NYSE: PFE) R&D facility in Groton, Connecticut. The project is part of a 20-year power purchase agreement between a FuelCell subsidiary and Pfizer. To view the full press release, visit:  http://nnw.fm/jAhU4 About FuelCell Energy Direct FuelCell® power plants are generating ultra-clean, efficient and reliable power on three continents, affordably providing continuous distributed power generation to a variety of industries including utilities, commercial and municipal customers.  The Company’s power…

Continue Reading

FridayNov 04, 2016 11:14 am

Clean Diesel Technologies, Inc. (CDTI) to Raise $10.3M in Private Placement; Shares Lower

Clean Diesel Technologies (NASDAQ: CDTI) shares tumbled in morning trade after the company announced its plans to raise about $10.3 million in a private placement of common stock priced at $2 per share. “Together with the successful repositioning of the company and the elimination of approximately $8.9 million in debt in August, this financing supports our continued execution of our advanced materials business strategy by providing us a stronger financial foundation. This financing also represents a key milestone as we seek to achieve scale and profitability, as well as build long-term shareholder value,” company CEO Matthew Beale stated in the…

Continue Reading

FridayNov 04, 2016 11:12 am

MGT Capital Investments, Inc. (MGTI) to Acquire Technology Interests, Forego Appeal of NYSE Listing Decision

Shares of MGT Capital Investments, Inc. (OTC: MGTI) are higher after the company announced its plans to proceed its Asset Purchase Agreement for D-Vasive, which includes the acquisition of Demonsaw, rather than appealing the decision of the NYSE to delist MGT's common stock. “This decision is based on our belief that an appeal would have little likelihood of success given the lack of transparency the NYSE provided prior to the appeal deadline,” MGT stated in the news release. Upon closing of the deal, the company said it expects to be listed on OTCQB; John McAfee and Eric "Eijah" Anderson will…

Continue Reading

ThursdayNov 03, 2016 2:30 pm

Alternet Systems, Inc. (ALYI) Inks LOI with North American Cannabis Holdings, Inc. (USMJ), Aims for Cannabis Retail Payment System

Shares of Alternet Systems, Inc. (OTC: ALYI) are trading higher after North American Cannabis Holdings, Inc. (OTC: USMJ) announced a Letter of Intent between the two companies, with an end goal of bringing a cannabis retail payment system to market. The LOI is the initial advancement toward a “comprehensive contract” under which Alternet would acquire select assets from North American Cannabis Holdings, potentially enabling Alternet to leverage its financial software industry experience and introduce a cannabis retail payment system. To view the full press release, visit:  http://nnw.fm/i3iLZ About Alternet Systems, Inc. Alternet Systems, Inc. (ALYI) invests in innovative ways to…

Continue Reading

ThursdayNov 03, 2016 11:29 am

Curis, Inc. (CRIS) Posts Wider Q3 Loss; Shares Higher

Shares of Curis (NASDAQ: CRIS) this morning posted a third quarter net loss of $28.3 million, or $(0.21) per share, on revenues of $1.8 million vs. a net loss of $5.5 million, or $(0.04) per share, on revenues of $2.0 million for the third quarter of 2015. The net loss for the 2016 quarter includes a non-cash in-process research and development charge of $18.0 million related to the amendment of Curis's license agreement with Aurigene. To view the full press release, visit: http://nnw.fm/3uHzF About Curis, Inc. Curis is a biotechnology company focused on the development and commercialization of innovative and…

Continue Reading

ThursdayNov 03, 2016 11:28 am

Achillion Pharmaceuticals, Inc. (ACHN) Posts Q3, Nine-Month Results; Shares Tumble

Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are sharply lower after the company reported its third quarter and nine-month financial results. Achillion posted a third-quarter net loss of $20.7 million or $0.15 per share, compared with net income of $26.3 million or $0.19 per share for the third quarter of 2015.  For the nine months ended September 30, 2016, Achillion reported a net loss of $57.3 million, compared to a net loss of $22.0 million in the same period in 2015. The company also said it will present at the 58th Annual Meeting of the American Society of Hematology (ASH) in San…

Continue Reading

ThursdayNov 03, 2016 11:26 am

BioLineRx Ltd. (BLRX) Announces Positive Data for BL-8040 Oncology Platform; Shares Inch Higher

BioLineRx Ltd. (NASDAQ/TASE: BLRX) is trading higher after the company reported positive results for BL-8040, its leading oncology platform, that will be presented at the 58th American Society of Hematology (ASH) Annual Meeting and Exhibition in San Diego taking place December 3-6, 2016. “In particular, clinical studies show that BL-8040 acts selectively on chemotherapy-resistant cells, which may be beneficial in reduction of residual disease and supports the incorporation of BL-8040 in front-line treatment settings such as AML consolidation. Such studies are currently ongoing. We are also encouraged to see, in pre-clinical models, a synergistic effect between BL-8040 and Venetoclax, and…

Continue Reading

ThursdayNov 03, 2016 11:25 am

Moxian, Inc.’s (MOXC) Strengthens B2C Reach via Mobile Apps

With the exponential value of mobile marketing for business, organizations are exploring innovative ways to better reach their audiences. Effective business to Consumer (B2C) marketing encompasses a wide variety of tools to achieve this goal, including social media, specifically designed content for use on mobile device, hyper-targeted ads, and more. China-based Moxian (OTCQB: MOXC) operates within this realm, offering social media marketing and promotion platforms via two mobile friendly applications: the Moxian+ Business app and the Moxian+ User app. “Since social media in particular is widely used on mobile devices, companies now need to make sure that all aspects of…

Continue Reading

WednesdayNov 02, 2016 10:51 am

Verastem, Inc. (VSTM) Licenses Infinity Pharmaceuticals’ (INFI) Cancer Treatment Candidate

Verastem, Inc. (NASDAQ: VSTM) and Infinity Pharmaceuticals (NASDAQ: INFI) are trading higher after the companies announced that Verastem has licensed exclusive worldwide rights to develop and commercialize Infinity's oncology product candidate duvelisib for the treatment of hematologic cancers, including chronic lymphocytic leukemia (CLL), indolent non-Hodgkin lymphoma (iNHL) and T cell lymphomas. To view the full press release, visit:  http://nnw.fm/WM3ut About Verastem, Inc. Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its…

Continue Reading